Ever Supreme
長聖國際生技股份有限公司
Ever Supreme is a Taiwan TPEx-listed biotechnology company; its most advanced asset is ADCV01 (Phase 2; recruiting, GBM), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ADCV01 | Autologous dendritic cells | Phase 2; recruiting | GBM | Taiwan | 2026-09-24 | Trial registry |
| CAR001 | — | Phase 2a enrollment authorized | Relapsed or refractory solid tumors | Taiwan | 2026-06-28 | Company disclosure |
| UMSC01 | Allogeneic umbilical cord mesenchymal stem cells | Phase 1 / Phase 2; active not recruiting | COVID-19 Infection | Taiwan | 2026-09-23 | Trial registry |
Key events
- CAR001 Phase 1 completed; TFDA authorized Phase 2a enrollment (company disclosure)